Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392049 | 0.83 | KDM4E (0.34) | KDM4EGAAHTT | |
| SCHEMBL31419341 | 0.73 | BLM (0.33) | — | |
| SCHEMBL15513698 | 0.72 | DRD2 (0.33) | ALDH1A1PKM | |
| SCHEMBL6890746 | 0.72 | LMNA (0.35) | GAAKDM5A | |
| SCHEMBL16908564 | 0.67 | KDM4E (0.32) | KDM4EGAAHTTALDH1A1 | |
| SCHEMBL17232580 | 0.65 | TSHR (0.43) | KDM4EKDM5A | |
| Bromoacetic Acid SCHEMBL1064789 | 0.64 | TSHR (0.48) | ALDH1A1PKM | |
| SCHEMBL1769618 | 0.63 | HTT (0.37) | KDM4EGAAHTTALDH1A1 | |
| SCHEMBL16908561 | 0.62 | KDM4E (0.33) | KDM4EGAAHTT | |
| SCHEMBL6738514 | 0.62 | LMNA (0.39) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2437790-B1 | CONJUGATION METHODS | IMMUNOGEN INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-20230045939-A1 | STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-3883944-A1 | STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE | Idorsia Pharmaceuticals Ltd (CH) | 2021-09-29 | — | — | EP | disclosed |
| US-10723731-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| US-10328141-B2 | Synthetic vaccines against Streptococcus pneumoniae type 1 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2018-07-05 | — | — | US | disclosed |
| US-9902724-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3019513-B1 | SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 1 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017189448-A1 | BIVALENT IMMUNOGENIC CONJUGATE FOR MALARIA AND TYPHOID | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-3153180-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M Innovative Properties Company (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2086577-B1 | CONJUGATES OF THE PLASMODIUM FALCIPARUM SURFACE PROTEIN PFS25 AS MALARIA VACCINE | US GOV HEALTH & HUMAN SERV (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8383133-B2 | Conjugates of Plasmodium falciparum surface proteins as malaria vaccines | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2012167088-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20110182929-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | NEW YORK UNIVERSITY | 2011-07-28 | — | — | US | disclosed |
| EP-2346523-A2 | A MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | The United States Of America,As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100183678-A1 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | The Govenment of the United States of America as represented by tge Secreatary of Health (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010040000-A2 | A MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2010-04-08 | — | — | WO | disclosed |
| CN-101557821-A | Conjugates of plasmodium falciparum surface proteins as malaria vaccines | US GOVERNMENT (US) | 2009-10-14 | — | — | CN | disclosed |
| EP-2086577-A2 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008048945-A2 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723731-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | IL2, ICOS, CD40 | KDM4E 3892/4885GAA 3064/4885HTT 4757/4885 |
| US-20230045939-A1 | STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE | DDOST, SI, CD4 | KDM4E 2876/4885GAA 1233/4885HTT 4630/4885 |
| US-20110182929-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | CD47, NASP, CD69 | KDM4E 4228/4885GAA 3592/4885HTT 4620/4885 |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | KDM4E 3892/4885GAA 3064/4885HTT 4757/4885 |
| US-20100183678-A1 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | CD4, RPS25, OSBP2 | KDM4E 4237/4885GAA 4186/4885HTT 3900/4885 |
| US-10328141-B2 | Synthetic vaccines against Streptococcus pneumoniae type 1 | NEU1, ALG1, CSGALNACT1 | KDM4E 2231/4885GAA 625/4885HTT 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.